Brain and neurology

Neurology-related clinical indications

Brain indications

Many important neurological diseases are accompanied with an autoimmune pathophysiology, so making it difficult to treat using conventional approaches. Therapeutic apheresis has shown to be a valuable and important treatment option in neurological diseases such as Guillain-Barré syndrome, myasthenia gravis and other peripheral conditions. There has also been great interest in progress made using extracorporeal techniques to treat idiopathic encephalitis and a subset of patients with multiple sclerosis. Furthermore, a new field of research has begun evaluating the scope for therapeutic apheresis to improve the cognitive functions of patients with vascular dementia.


Related products

1. Instruction for use (IFU) LIGASORB®, Art. Nr. F00001564, 35840318 / Mar.–May 2016
2. Dogan et al, Immunoadsorption therapy in autoimmune encephalitides. Neurology 26 Feb. 2016; 3(2): 207. Retreived from
3. Dorst et al, (2016) Immunoadsorption with regenerating columns in treatment of steroid-refractory relapse in multiple sclerosis and optic neuritis. Multiple Sclerosis Journal (Foster City) 3: 178.
4. Schneidewind et al, Immunoadsorption: A new therapeutic possibility for multiple sclerosis? Transfusion Science Mar. 1998; 19 Suppl: 59–63.
5. Karczewski et al, Agonistic autoantibodies to the α(1) -adrenergic receptor and the β(2) -adrenergic receptor in Alzheimer's and vascular dementia. Scandinavian Journal of Immunology May 2012; 75(5): 524–30.
6. Hempel et al, Immunoadsorption of agonistic autoantibodies against α1-adrenergic receptors in patients with mild to moderate dementia. Therapeutic Apheresis and Dialysis Oct. 2016; 20(5): 523–29.
7. Zinman et al, A pilot study to compare the use of the Excorim staphylococcal protein immunoadsorption system and IVIG in chronic inflammatory demyelinating polyneuropathy. Transfusion and Apheresis Science Nov. 2005; 33(3): 317-24.
8. Rech et al, Remission of demyelinating polyneuropathy with immunoadsorption, low dose corticosteroids and anti-CD20 monoclonal antibody. Therapeutic Apheresis and Dialysis June 2008; 12(3): 205–8.
9. Baggi et al, Effect of IgG immunoadsorption on serum cytokines in MG and LEMS patients. Journal of Neuroimmunology 15 September 2008; 201/202: 104–10.
10. Schwartz et al, Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: The sixth special issue. Journal of Clinical Apheresis 28 July 2013; 28(3): 145–284.